Outcome and survival of asymptomatic PML in natalizumab-treated MS patients. - sprookjes - yvandenbroek - TriplyDB

Outcome and survival of asymptomatic PML in natalizumab-treated MS patients.

Outcome and survival of asymptomatic PML in natalizumab-treated MS patients.

http://www.wikidata.org/entity/Q34562841

about

Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group Neuroimaging of Natalizumab Complications in Multiple Sclerosis: PML and Other Associated Entities An update on the use of natalizumab in the treatment of multiple sclerosis: appropriate patient selection and special considerations Neurological immune reconstitution inflammatory response: riding the tide of immune recovery Natalizumab-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: Findings from an Italian Independent Registry Revised Recommendations of the Consortium of MS Centers Task Force for a Standardized MRI Protocol and Clinical Guidelines for the Diagnosis and Follow-Up of Multiple Sclerosis MRI in the Diagnosis and Monitoring of Multiple Sclerosis: An Update.Use of natalizumab in multiple sclerosis: current perspectives.Brain Susceptibility Changes in a Patient with Natalizumab-Related Progressive Multifocal Leukoencephalopathy: A Longitudinal Quantitative Susceptibility Mapping and Relaxometry Study Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab.Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy.Current and Emerging Therapies in Multiple Sclerosis: Implications for the Radiologist, Part 2-Surveillance for Treatment Complications and Disease Progression.MRI in the assessment and monitoring of multiple sclerosis: an update on best practice.CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients.Risk of progressive multifocal leukoencephalopathy in patients with multiple sclerosis.Use of Natalizumab in Patients with Multiple Sclerosis: 2015 Update.Natalizumab in relapsing-remitting multiple sclerosis.Assessing understanding of individual risk and symptoms of progressive multifocal leukoencephalopathy in patients prescribed natalizumab for multiple sclerosis.Treatment-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: A Comprehensive Review of Current Evidence and Future Needs.Drug-induced progressive multifocal leukoencephalopathy in multiple sclerosis: European regulators' perspective.Natalizumab treatment of multiple sclerosis: new insights.Multiple sclerosis update: use of MRI for early diagnosis, disease monitoring and assessment of treatment related complications.Imaging Markers for Monitoring Disease Activity in Multiple Sclerosis.Progressive multifocal leukoencephalopathy in patients treated with fumaric acid esters: a review of 19 cases.MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance.Diagnostic performance of brain MRI in pharmacovigilance of natalizumab-treated MS patients.MRI characteristics of early PML-IRIS after natalizumab treatment in patients with MS.Insight into Metabolic 1H-MRS Changes in Natalizumab Induced Progressive Multifocal Leukoencephalopathy Brain Lesions.Laminar Cortical Hypointensities in Susceptibility-Weighted Imaging in a Case of Progressive Multifocal Leukoencephalopathy.Posterior fossa progressive multifocal leukoencephalopathy: first presentation of an unknown autoimmune disease.Imaging spectrum of immunomodulating, chemotherapeutic and radiation therapy-related intracranial effects.High-frequency MRI monitoring should be performed in natalizumab-treated MS patients with higher risk of PML - Commentary.Brain Magnetic Susceptibility Changes in Patients with Natalizumab-Associated Progressive Multifocal Leukoencephalopathy.Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis.High-frequency MRI monitoring should be performed in natalizumab-treated MS patients with higher risk of PML - YES.Asymptomatic progressive multifocal leukoencephalopathy: a case report and review of the literature.The still under-investigated role of cognitive deficits in PML diagnosis

P2860

Q26780412-FE5C5B45-425D-4C7D-9072-1E18633E1C12 Q26781389-2E569BAE-3F59-4E02-B6D2-5B99510A198A Q27009769-D958D731-7F78-4E08-ABD0-694B671D2A01 Q28082309-CE25C4B5-60E0-449A-84DD-3CCF64418ED4 Q28555138-435C4513-F554-4703-AABB-95A001E19F0C Q30278095-98C3E168-1DBA-423C-9C20-CD6803975C69 Q30981999-3816EC3B-006D-472C-8513-4FD685BCA591 Q31114633-742E2181-33D4-4960-AADF-9FD6E5EAC030 Q33810020-19D52A81-72AB-4D34-9A1D-14F4D1E5CECB Q36073992-AF85D925-A191-4AE1-9F93-9FFD782F9F3E Q36234255-5B9A085D-5621-494C-A95E-401A1B5C04E3 Q36352813-1B841662-B59D-4BC5-AFBB-259348C5355E Q36400004-A4172AD3-30E5-4740-8F49-431E3E88385F Q36645170-D1F7B876-66D2-4316-9429-E0B3ED4B7767 Q38591114-01008EDE-36BE-4549-903E-154A6589EB21 Q38616689-9106B408-8B68-4228-B926-91AB15DDC63F Q38786252-0DF66E92-F557-4D95-99A6-809ADAA341F4 Q38793624-B83B820D-9698-4607-89E5-555A0F542465 Q38815391-C8F7084F-89B3-4FEC-A50E-AECAADBBFA69 Q39046213-9202F30E-8DB0-47C2-B4F0-A95AC52397C7 Q39048568-9264CA5F-A158-4BF9-AA3D-D708BC96BD7D Q39211049-DC76A978-0DD3-4339-A6FD-183297CD2F3A Q39247449-256E2B75-28A5-4A26-9968-ABE46E798F87 Q39325788-D99AC03C-A4DC-4B45-B398-518182A3CB0C Q40619670-C4196AC0-6F6A-4603-8382-D473EEABDFE9 Q41126166-6D59B98E-A244-432B-8053-9CD7A6AD67F6 Q41361912-3FF53D90-4CAE-4AB7-889B-AA9E6B2F5D47 Q41455235-9816FBCC-E5F2-4B77-819E-BB8D2387EEB8 Q42362984-79521C0E-8B66-4FD0-9DAE-26EFA0DDA070 Q42650343-87CBBCC0-AF33-4BA1-9863-92B53CE8F529 Q50079049-2C21B178-5D49-4717-9983-01670DCADBB0 Q51100906-6FA9E159-7876-4412-AE44-94B6F3FFC936 Q52150367-3E93CABA-DC5A-45A4-9B7D-18ABE9FEEF3D Q52659119-EE81C23D-B398-4F84-868B-A20B8DD5D2D5 Q54607295-F8016F81-B548-46DD-94EB-7CAA35CDFD4C Q55516242-7ADD2278-3874-412E-9C56-8E7051D08D3E Q58864832-5EF82DBB-82B8-42E6-B021-CB2E4DAE5FF4

P2860

Outcome and survival of asymptomatic PML in natalizumab-treated MS patients.

http://www.wikidata.org/entity/Q34562841

description

2014 nî lūn-bûn

@nan

2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Outcome and survival of asymptomatic PML in natalizumab-treated MS patients.

@ast

Outcome and survival of asymptomatic PML in natalizumab-treated MS patients.

@en

Outcome and survival of asymptomatic PML in natalizumab-treated MS patients.

@nl

type

label

Outcome and survival of asymptomatic PML in natalizumab-treated MS patients.

@ast

Outcome and survival of asymptomatic PML in natalizumab-treated MS patients.

@en

Outcome and survival of asymptomatic PML in natalizumab-treated MS patients.

@nl

prefLabel

Outcome and survival of asymptomatic PML in natalizumab-treated MS patients.

@ast

Outcome and survival of asymptomatic PML in natalizumab-treated MS patients.

@en

Outcome and survival of asymptomatic PML in natalizumab-treated MS patients.

@nl

P1433

Q34562841-FB466DEF-93AE-4E55-A90D-B2F3133CCCF2

P1476

Q34562841-FDC228A5-8B94-47CC-BFBB-F55D2277B2B0

P2093

Q34562841-065E47E0-3C98-4814-AAC9-F3FB02131AFB

Q34562841-513F05BD-CF3F-4DD5-AF89-C32CCE71876A

Q34562841-523675D5-49E5-486D-8BA5-48D96DA1882E

Q34562841-78CB2BD4-AF05-477A-B769-953CD2F788E9

Q34562841-9111A4AC-6268-41E1-87CF-EA85327CD404

Q34562841-97D85624-7B71-44FD-98F3-B7E83F28BB82

Q34562841-99866F65-B986-43B5-AC31-5C5BC72FF9A0

Q34562841-9C140C65-DCCA-417F-A553-D01A39C5C93F

Q34562841-9F7C1B6C-1637-4B40-B396-A76E1D9192E5

Q34562841-DEEDA1F7-6255-4642-B56D-D5B04DC37C83

P2860

Q34562841-05ED7440-3200-4968-8181-991518C52EA4

Q34562841-0EB1EFCF-A6FD-4E5B-8F65-F55B3E3CC143

Q34562841-12ECAF86-BC12-4A0B-B872-510376F8F9A0

Q34562841-26C35BA5-82BA-482D-913F-F2BE195E4364

Q34562841-333A8AC3-4DDE-4266-9D37-D729600A54C3

Q34562841-39282649-30A8-4D0D-8353-A4493EF3BDEE

Q34562841-39D944C8-E655-4358-A243-B97CD7675D19

Q34562841-3CB946BC-356F-44DA-97E5-C28FB3A202F0

Q34562841-3DB3259C-1D9A-45E9-811D-9B8991232759

Q34562841-55094825-A232-4522-8540-4F2011519A19

P304

Q34562841-81E99B57-5C1A-42F4-A6D6-633FE038CB50

P31

Q34562841-8D4BC3A8-378D-41CA-BB71-DE7774779659

P356

Q34562841-07DBFD29-1CE0-4F19-BC03-A2A556E8209B

P433

Q34562841-32CBBD2F-BB48-4480-9CDB-0B1EB4C1E375

P478

Q34562841-018118FA-E1A5-4E16-B5D3-C1A9EDC9041D

P577

Q34562841-F74BF2FC-4AE1-49AC-B6E7-1ABEEB62B685

P5875

Q34562841-19804D83-01F9-40E7-B4A2-5B5C30E64A83

P698

Q34562841-62CE287A-CCD0-4743-89AB-D4C111824C0A

P921

Q34562841-6F41C6B3-4629-4894-AB6C-62A7C523DEDB

P932

Q34562841-3004F16E-2A0F-44B0-91E0-AA9B4E54AF51

P356

P1433

Annals of clinical and translational neurology

P1476

Outcome and survival of asymptomatic PML in natalizumab-treated MS patients.

@en

P2093

Carmen Bozic

http://www.w3.org/2001/XMLSchema#string

Gary Bloomgren

http://www.w3.org/2001/XMLSchema#string

James McIninch

http://www.w3.org/2001/XMLSchema#string

Jeffrey Philip

http://www.w3.org/2001/XMLSchema#string

Made Wenten

http://www.w3.org/2001/XMLSchema#string

Mike P Wattjes

http://www.w3.org/2001/XMLSchema#string

Nancy Richert

http://www.w3.org/2001/XMLSchema#string

Sandra Richman

http://www.w3.org/2001/XMLSchema#string

Sarah Gheuens

http://www.w3.org/2001/XMLSchema#string

Shoibal Datta

http://www.w3.org/2001/XMLSchema#string

P2860

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy

Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring

Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies

LOWESS: A Program for Smoothing Scatterplots by Robust Locally Weighted Regression

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy.

PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section.

The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy.

Progressive multifocal leukoencephalopathy in HIV-1 infection.

P304

755-764

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ACN3.114

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P577

2014-10-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

266679177

http://www.w3.org/2001/XMLSchema#string

P698

25493267

http://www.w3.org/2001/XMLSchema#string

P921

P932

4241803

http://www.w3.org/2001/XMLSchema#string